trending Market Intelligence /marketintelligence/en/news-insights/trending/0zjOeOSLmLlricnqJU7FHg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US FDA approves Dexcom's glucose monitoring system

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA approves Dexcom's glucose monitoring system

The U.S. FDA approved DexCom Inc.'s G5 Mobile CGM system, a continuous glucose monitoring system, with a non-adjunctive designation.

In July, an FDA selected panel of experts deemed the system safe and effective, with its benefits outweighing the risks with the proposed indications for use. The FDA has followed the expert recommendation and made the system the first and only continuous glucose monitoring system in the U.S. to have a non-adjunctive designation.

The new non-adjunctive indication expands the use of the system as a replacement to finger stick glucose testing for diabetes treatment decisions. With the new label indication, the system only requires two finger pricks per day for calibration.